Ernexa Therapeutics (ERNA) Cost of Revenue (2016 - 2024)
Historic Cost of Revenue for Ernexa Therapeutics (ERNA) over the last 13 years, with Q3 2024 value amounting to $60000.0.
- Ernexa Therapeutics' Cost of Revenue fell 5000.0% to $60000.0 in Q3 2024 from the same period last year, while for Dec 2024 it was $216000.0, marking a year-over-year decrease of 847.46%. This contributed to the annual value of $96000.0 for FY2024, which is 5932.2% down from last year.
- According to the latest figures from Q3 2024, Ernexa Therapeutics' Cost of Revenue is $60000.0, which was down 5000.0% from $95000.0 recorded in Q2 2024.
- In the past 5 years, Ernexa Therapeutics' Cost of Revenue ranged from a high of $950000.0 in Q1 2020 and a low of $50000.0 during Q1 2023
- For the 3-year period, Ernexa Therapeutics' Cost of Revenue averaged around $200285.7, with its median value being $66000.0 (2023).
- Within the past 5 years, the most significant YoY rise in Ernexa Therapeutics' Cost of Revenue was 2200.0% (2024), while the steepest drop was 5000.0% (2024).
- Over the past 3 years, Ernexa Therapeutics' Cost of Revenue (Quarter) stood at $950000.0 in 2020, then plummeted by 93.05% to $66000.0 in 2023, then dropped by 9.09% to $60000.0 in 2024.
- Its Cost of Revenue stands at $60000.0 for Q3 2024, versus $95000.0 for Q2 2024 and $61000.0 for Q1 2024.